

Bethan Sarah Woods

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6066050/publications.pdf>

Version: 2024-02-01

17
papers

802
citations

1163117

8
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1856
citing authors

#	ARTICLE	IF	CITATIONS
1	Classifying information-sharing methods. BMC Medical Research Methodology, 2021, 21, 107.	3.1	6
2	Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. Health Economics (United Kingdom), 2021, 30, 2649-2666.	1.7	8
3	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. Value in Health, 2021, 24, 1828-1834.	0.3	22
4	Concomitant health benefits package design and research prioritisation: development of a new approach and an application to Malawi. BMJ Global Health, 2021, 6, e007047.	4.7	1
5	Practical metrics for establishing the health benefits of research to support research prioritisation. BMJ Global Health, 2020, 5, e002152.	4.7	3
6	Simulation Modeling and Metamodeling to Inform National and International HIV Policies for Children and Adolescents. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, S49-S57.	2.1	12
7	Appraising the value of evidence generation activities: an HIV modelling study. BMJ Global Health, 2018, 3, e000488.	4.7	7
8	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of Medical Economics, 2017, 20, 8-18.	2.1	7
9	Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. PLoS ONE, 2017, 12, e0172749.	2.5	51
10	Acupuncture for chronic pain and depression in primary care: a programme of research. Programme Grants for Applied Research, 2017, 5, 1-316.	1.0	27
11	Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. Heart, 2016, 102, 1742-1749.	2.9	30
12	Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value in Health, 2016, 19, 929-935.	0.3	589
13	Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain. BMC Medical Research Methodology, 2016, 16, 131.	3.1	11
14	Bayesian parameterization for network meta-analysis. Research Synthesis Methods, 2016, 7, 306-313.	8.7	17
15	Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. Pharmacoeconomics, 2016, 34, 981-992.	3.3	4
16	Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?. Pharmacoeconomics, 2016, 34, 427-433.	3.3	6
17	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.. Journal of Clinical Oncology, 2016, 34, 19-19.	1.6	1